摘要
目的观察西妥昔单抗（Cetuximab）单用及与丝裂霉素（MMC）、阿霉素（ADM）、羟基喜树碱（HCPT）联用对人膀胱癌T-24细胞的增殖抑制作用。方法选用Cetuximab（0～500mg／L）和MMC（0～50mg／L）、ADM（0～10mg／L）、HCPT（0～10mg／L），单独或联合作用于T-24细胞，CCK-8法检测细胞增殖抑制作用；金氏公式判断两药联用的协同效应；流式细胞仪检测凋亡率。结果Cetuximab、MMC、ADM、HCPT对T-24细胞存在程度不同的增殖抑制作用，其20％～30％抑制的工作浓度（IC20-30）分别为20．0、0．5、0．1、0．2mg／L；以该浓度的Cetuximab分别与MMC、ADM、HCPT联合，协同指数q值分别为1．22、1．17、1．25；联合组凋亡率分别为（18．9±1．9）％、（20．1±1．9）％、（21．6±2．4）％，显著高于单独药物组（P〈0．05）。结论Cetuximab对膀胱癌T-24细胞存在一定的增殖抑制作用，与化疗药物MMC、ADM、HCPT联合均可取得较好的协同效应，这可能与其进一步促进T-24细胞凋亡有关。
Objective To investigate the proliferation inhibition of Cetuximab or combined with chemotherapeutics on human bladder cancer cell line T-24. Methods Increasing concentrations of cetuximab （0-500 mg/L） and chemotherapeutics including MMC （0-50 mg/L）, ADM （0-10 mg/L）, HCPT （0- 10 rag/L） alone or in combination were administrated to human bladder cancer cell line T-24 for 72 h. CCK-8 assay was used to detect the inhibitory effect and King＇ s Formula was used to determine the synergistic effect. Flow cytometry technique was also applied to find out the influence of IC20.30 concentration of cetuximab or combined with of IC20-30 concentration of chemotherapeutics on the cells apoptosis. Results The differently inhibitory effects of cetuximah and chemotherapeutics were observed. The IC20-30 concentrations of Cetuximab and MMC, ADM, HCPT at 20.0,0.5,0.1,0.2 mg/L respectively were obtained and subsequently used in the following experiments. The combination index（q） was 1.22,1.17,1.25 and the apoptosis rate of 72 h was （ 18.9 ± 1.9 ） % , （20. 1 ± 1.9 ） % , （21.6 ± 2.4 ） % respectively （ P 〈 0.05, compared with single cetuximab or ehemotherapeutics group）. Conclusion Cetuximab combined with chemotherapeutics synergistically increases the inhibitory effect on T-24 cells, possibly through the further induction of apoptosis.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2009年第10期1247-1249,共3页
Chinese Journal of Experimental Surgery
